Search - tctmd.com

Displaying 81 - 100 of 103

Sort: Relevancy | Date

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

June 19, 2017

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

News Daily News

Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value

May 04, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

TCTMD’s Top 10 Most Popular Stories for February 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

March 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

December 29, 2016

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

December 29, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

November 30, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

October 29, 2016

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

News Daily News

FDA: No More Chances for Embattled Coagulation Monitoring System

July 13, 2016

News Daily News

FDA: No Más Oportunidades para el Acosado Sistema para Monitorizar la Coagulación

July 13, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

April 29, 2016

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

心力衰竭会使ACS后的结果恶化，阿哌沙班不能带来益处

January 28, 2015

News Daily News

La IC Empeora los Resultados Post-SCA No observándose Beneficio alguno con Apixaban

January 28, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

January 28, 2015

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.